RT Journal Article
T1 Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience.
A1 Labrador, Jorge
A1 Saiz-Rodríguez, Miriam
A1 de Miguel, Dunia
A1 de Laiglesia, Almudena
A1 Rodríguez-Medina, Carlos
A1 Vidriales, María Belén
A1 Pérez-Encinas, Manuel
A1 Sánchez-Sánchez, María José
A1 Cuello, Rebeca
A1 Roldán-Pérez, Alicia
A1 Vives, Susana
A1 Benzo-Callejo, Gonzalo
A1 Colorado, Mercedes
A1 García-Fortes, María
A1 Sayas, María José
A1 Olivier, Carmen
A1 Recio, Isabel
A1 Conde-Royo, Diego
A1 Bienert-García, Álvaro
A1 Vahi, María
A1 Muñoz-García, Carmen
A1 Seri-Merino, Cristina
A1 Tormo, Mar
A1 Vall-Llovera, Ferran
A1 Foncillas, María-Ángeles
A1 Martínez-Cuadrón, David
A1 Sanz, Miguel Ángel
A1 Montesinos, Pau
K1 acute myeloid leukemia
K1 refractory
K1 relapsed
K1 venetoclax
AB The effectiveness of venetoclax (VEN) in relapsed or refractory acute myeloid leukemia (RR-AML) has not been well established. This retrospective, multicenter, observational database studied the effectiveness of VEN in a cohort of 51 RR-AML patients and evaluated for predictors of response and overall survival (OS). The median age was 68 years, most were at high risk, 61% received ≥2 therapies for AML, 49% had received hypomethylating agents, and ECOG was ≥2 in 52%. Complete remission (CR) rate, including CR with incomplete hematological recovery (CRi), was 12.4%. Additionally, 10.4% experienced partial response (PR). The CR/CRi was higher in combination with azacitidine (AZA; 17.9%) than with decitabine (DEC; 6.7%) and low-dose cytarabine (LDAC; 0%). Mutated NPM1 was associated with increased CR/CRi. Median OS was 104 days (95% CI: 56-151). For the combination with AZA, DEC, and LDAC, median OS was 120 days, 104 days, and 69 days, respectively; p = 0.875. Treatment response and ECOG 0 influenced OS in a multivariate model. A total of 28% of patients required interruption of VEN because of toxicity. Our real-life series describes a marginal probability of CR/CRi and poor OS after VEN-based salvage. Patients included had very poor-risk features and were heavily pretreated. The small percentage of responders did not reach the median OS.
SN 2072-6694
YR 2022
FD 2022-03-29
LK http://hdl.handle.net/10668/20882
UL http://hdl.handle.net/10668/20882
LA en
DS RISalud
RD Apr 7, 2025